Anixa Biosciences
ANIX
42 hedge funds and large institutions have $10.2M invested in Anixa Biosciences in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
44% more call options, than puts
Call options by funds: $122K | Put options by funds: $85K
20% more funds holding
Funds holding: 35 → 42 (+7)
0.87% more ownership
Funds ownership: 10.61% → 11.48% (+0.87%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
33% less capital invested
Capital invested by funds: $15.2M → $10.2M (-$4.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$480K |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
+$105K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$79.6K |
| 4 |
Goldman Sachs
New York
|
+$66.6K |
| 5 |
VF
Virtu Financial
New York
|
+$66.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$108K |
| 2 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
-$78K |
| 3 |
Two Sigma Investments
New York
|
-$63.5K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$22.2K |
| 5 |
BlackRock
New York
|
-$20.7K |
ANIX Hedge Fund Activity: Q4 2021 in Review
42 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2021, worth a combined $10.2M — down 33% from $15.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ANIX positions and 3 closed out — a net gain of 7 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $480K. The largest seller was Susquehanna International Group, cutting an estimated $108K.
- 42 institutional investors held Anixa Biosciences (ANIX) as of Q4 2021, up from 35 in Q3 2021.
- Funds reported $10.2M of Anixa Biosciences stock for Q4 2021, down 33% quarter-over-quarter.
- 10 funds opened new Anixa Biosciences positions in Q4 2021 and 3 closed out, a net change of +7 holders.
- The largest Anixa Biosciences buyer in Q4 2021 was Renaissance Technologies, an estimated $480K added.
- The largest Anixa Biosciences seller in Q4 2021 was Susquehanna International Group, an estimated $108K sold.
Based on aggregated 13F filings for Q4 2021.